David Moller, an experienced drug developer, has joined Poxel SA as chief scientific officer to support the advancement of its programmes in Type 2 diabetes and non-alcoholic steatohepatitis. He will be based in Boston, US.
Dr Moller was previously CSO at Sigilon Therapeutics Inc, which is working on drug delivery technology. Prior to that, he worked at Eli Lilly and Company where he held a number of senior roles including head of endocrine and cardiovascular research. Dr Moller obtained a Bachelor of Science degree from Brown University and medical degree from the University of Cincinnati, both in the US.
Poxel announced the appointment on 23 January 2020.
Copyright 2020 Evernow Publishing Ltd